Tracxn Technologies Ltd Q1 FY27 Results

Delivered result confirms 21.1 Cr total revenue, 2.9% QoQ; India 10.6 Cr consistent with call

If India 10.6 and total 21.1, international ~10.5; prior quarter ~10.3 (estimated), consistent with turnaround

Call confirms 8% QoQ, prior year IB 20% YoY; acceleration from 20% to 30% annualized is claim. Supported by segment data.

Call explicitly states this figure

Analyst Jignesh cited this, management confirmed. Deliverable result does not contradict.

Prior FY26: India 14% YoY. Q1 FY27: 4.4% QoQ = ~19% annualised. International was contracting; now +1.4% QoQ. Segment-wise playbook delivering vs. prior stagnation narrative.

VC was 1/3 of revenue (peak); management says now 'lower than half that' but 'still decent' (not disclosed exact %). IB 30% growth, corporate 30% growth offsetting VC contraction.

Tracxn Connector (Claude/ChatGPT/Gemini), AI Assistant on platform, agentic workflows live in Q1 FY27. Expected to contribute revenue in FY27 but not yet material.

Management claims 'once growth re-accelerates, margins expand at 80% incremental EBITDA conversion' (historical reference). But Q1 still shows −4.2 Cr EBITDA, −3 Cr PAT; no near-term profitability inflection guidance.

EBITDA expansion is predictable once growth re-accelerates. Example: when top line +20 Cr, EBITDA +15 Cr in one year. High-margin business, non-linear trickle-down. Focused on initiatives; margin expansion follows.

Deal volumes at 10-year low, large rounds down. VC segment (largest) impacted. Pivoted to IB, corporate sales by augmenting offering. Takes 3–4 quarters to build/launch; then growth comes. IB/corporate now 20–30% growth vs. VC still flat.

Bloomberg = public-market data. Private markets seldom use it; sourcing/use cases different. Even at 1B+ AUM funds, didn't use Bloomberg for private deals. We compete vs. 3–4 players per segment, not Bloomberg. We take 80–90% standard offering, add gaps to be best-in-class quickly.

IB India proven. Next: corporate sales (M&A, innovation) also scaling phase 3. UK/US IB in phase 2. Multiple segments in different phases. VC was 1/3; now other segments growing faster, share declining but still 'decent' (exact % not disclosed).

All segments hit 2 years back. Tested India first (easier to scale sales, see output), replicated playbook now internationally. IB UK/US in phase 2. Data launches just done and upcoming. AI Suite rolled out. Scaling sales internationally. Early good signs Q1, expect notable improvement next quarters.

Green shoots: segment-wise acceleration (dozen target segments, QoQ improving pace). IB 20% YoY last year, now 30% annualised. Corporate 30% growth. Takes 3–4 quarters to build/launch data; then immediate uptick in sales conversions (15–20% to 50%). Working closely on this; excited about results.

Industry worst 2 years, impacted global players. We pivoted to other segments, growing those. Expect momentum to continue. (Vague on inflection timeline.)

Yes—quarterly contract prices increased, deferred revenue increased, signed good accounts. There's momentum.

Yes, those are interesting numbers. We expect momentum to continue.

~60 net new accounts Q1 QoQ. ~300+ users QoQ. ASP per account ~3.6 lakh/year, per user ~1.3 lakh/year. Mix changed, ASP declined a bit, now stabilising. Q1 first quarter in some time with minor ASP increase. Stabilised now.

Tracxn Lite users NOT in reported 6,534 count (only paid accounts). Freemium marketing channel. 300k+ signups since launch. Top-of-funnel acquisition, PLG. Not counted in paid metrics.

Based on Q1 4.4% QoQ annualising to ~19%, management claims momentum to continue. Vertical playbook scaling across multiple BUs. Sales team doubling Dec 2026 expected to drive further acceleration.

Q1 international +1.4% QoQ (positive inflection). Data launches, sales scaling, AI products expected to drive improvement H2 FY27. Management says 'should show impact next quarter' but vague on magnitude.

No specific FY27 consolidated revenue target given (e.g., '₹85 Cr'). Only component guidance (India 15–20%, international TBD). Given YoY flat this quarter, near-term inflection uncertain.

Example: 20 Cr revenue increase → 15 Cr EBITDA increase (historical). But Q1 shows −4.2 Cr EBITDA with only 2.9% QoQ revenue growth. No near-term EBITDA inflection expected if revenue stays flat.

Management expects current QoQ 12.5% expense increase to annualise to ~10%. Sales team doubling to 60 by Dec 2026 will add near-term costs before revenue upside realises.

Deal volumes at 10-year low; VC funding frozen. VC was 1/3 of revenue (peak). Revenue flat despite claimed segment acceleration suggests headwinds offsetting wins. If macro stays weak, VC recovery delayed, consolidated revenue stays flat longer.

Playbook proven in IB India only (1 segment); rolling out across 12+ segments simultaneously. Each vertical requires 3–4 quarters data-build, sales-ramp, conversion-lift. If any segment fails to execute or market adoption is slower than modeled, consolidated growth stalls further.

IB segment now 30% growth driver; corporate 30% growth. If both segments customer-concentrated (e.g., top 5 IB customers 50% of segment revenue), loss of 1–2 large accounts could impact growth. ASP per account 3.6L; with 2,350 accounts, top ~50 = material revenue.

International revenue contracting for 2+ years (US/Europe de-growth). Just turned positive QoQ (+1.4%) in Q1. Multiple data launches and sales initiatives promised, but unproven. If international stalls again or takes longer to ramp, consolidated growth cap remains below targets.

PAT −3 Cr (−13.3% margin), EBITDA −4.2 Cr (−20.1% margin). Expense growth 18% YoY. Free cash flow −2.2 Cr Q1. While 88.2 Cr cash provides 8+ years of runway at current burn, escalating headcount (sales team doubling, data teams) before revenue inflects could accelerate burn. No near-term profitability guidance.